Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-10

Development of tuberculosis vaccine with consistent efficacy in differentregions of the world

Objective

* To construct and investigate the efficacy and mode of action of experimental vaccines in animal models.
* To study the interactions between environmental mycobacteria and vaccine induced protection in animal models.
Expected Outcome

An identification and recombinant production of novel immunodominant antigens. An overview of the immunogenicity and protective efficacy of these. An overview of the mycobacterial antigens that are relevant for protective immunity against tuberculosis in humans

2) Investigation of experimental vaccines in animal models

Objectives
* To construct and investigate the efficacy and mode of action of experimental vaccines in animal models.
* To study the interactions between environmental mycobacteria and vaccine induced protection in animal models.

Activities
Production of a fusion protein consisting of ESAT-6 and Ag85B. Testing of the immunogenicity of this hybrid molecule. The level of acquired resistance following immunization with the hybrid in the presence or absence of various cytokines and inhibitors will be studied. The influence of pre-vaccination exposure to environmental mycobacteria on immune responses as well as BCG replication will be monitored and the influence on subsequent protection against tuberculosis evaluated.

Expected outcome
Characterization of the mechanisms underlying the vaccine induced protective immunity. Information on the interaction between immunization and
sensitization with environmental mycobacteria.

3) Production of ST-CF/DDA vaccine for human use

Objectives
* To produce and test the new ST-CF/DDA vaccine in humans.
Production of an extensive panel of recombinant Culture Filtrate Proteins (CFPs) from cultures of virulent M. tuberculosis. Characterization of the antigens expressed by environmental mycobacteria isolated from the Karonga District in Malawi. Investigation of the recognition of these antigens i) in vitro by cells from memory immune mice and recently infected mice, ii) in vitro by defined groups of TB infected, BCG vaccinated, and unimmunized human donors, and iii) in vivo by guinea pigs (skintest). The protective efficacy of the antigens alone or in combination will finally be evaluated in mice and guinea pigs.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSC - Cost-sharing contracts

Coordinator

STATENS SERUM INSTITUT
EU contribution
No data
Address
5,Artillerivej 5
2300 KOEPENHAGEN
Denmark

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (5)

My booklet 0 0